299 related articles for article (PubMed ID: 9338007)
41. Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.
Gordon EM; Levy JP; Reed RA; Petchpud WN; Liu L; Wendler CB; Hall FL
Int J Oncol; 2008 Oct; 33(4):665-75. PubMed ID: 18813779
[TBL] [Abstract][Full Text] [Related]
42. Virus-directed enzyme prodrug therapy using CB1954.
Grove JI; Searle PF; Weedon SJ; Green NK; McNeish IA; Kerr DJ
Anticancer Drug Des; 1999 Dec; 14(6):461-72. PubMed ID: 10834268
[TBL] [Abstract][Full Text] [Related]
43. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
44. Nitroreductase activation of CB1954--an alternative 'suicide' gene system.
Bailey SM; Hart IR
Gene Ther; 1997 Feb; 4(2):80-1. PubMed ID: 9081709
[No Abstract] [Full Text] [Related]
45. Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy.
Deharvengt S; Wack S; Aprahamian M; Hajri A
J Gene Med; 2005 May; 7(5):672-80. PubMed ID: 15580629
[TBL] [Abstract][Full Text] [Related]
46. Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil.
Palmer DH; Milner AE; Kerr DJ; Young LS
Br J Cancer; 2003 Sep; 89(5):944-50. PubMed ID: 12942130
[TBL] [Abstract][Full Text] [Related]
47. Tumor-specific intravenous gene delivery using oncolytic adenoviruses.
Zhan J; Gao Y; Wang W; Shen A; Aspelund A; Young M; Laquerre S; Post L; Shen Y
Cancer Gene Ther; 2005 Jan; 12(1):19-25. PubMed ID: 15514685
[TBL] [Abstract][Full Text] [Related]
48. Combining gene and immunotherapy for prostate cancer.
Young JG; Green NK; Mautner V; Searle PF; Young LS; James ND
Prostate Cancer Prostatic Dis; 2008; 11(2):187-93. PubMed ID: 17726452
[TBL] [Abstract][Full Text] [Related]
49. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals.
Bhaumik S; Sekar TV; Depuy J; Klimash J; Paulmurugan R
Gene Ther; 2012 Mar; 19(3):295-302. PubMed ID: 21753794
[TBL] [Abstract][Full Text] [Related]
50. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum.
Theys J; Landuyt W; Nuyts S; Van Mellaert L; van Oosterom A; Lambin P; Anné J
Cancer Gene Ther; 2001 Apr; 8(4):294-7. PubMed ID: 11393282
[TBL] [Abstract][Full Text] [Related]
51. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.
Prosser GA; Copp JN; Mowday AM; Guise CP; Syddall SP; Williams EM; Horvat CN; Swe PM; Ashoorzadeh A; Denny WA; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2013 Apr; 85(8):1091-103. PubMed ID: 23399641
[TBL] [Abstract][Full Text] [Related]
52. Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice.
Cao X; Ju DW; Tao Q; Wang J; Wan T; Wang BM; Zhang W; Hamada H
Gene Ther; 1998 Aug; 5(8):1130-6. PubMed ID: 10326037
[TBL] [Abstract][Full Text] [Related]
53. Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle.
Guise CP; Grove JI; Hyde EI; Searle PF
Gene Ther; 2007 Apr; 14(8):690-8. PubMed ID: 17301844
[TBL] [Abstract][Full Text] [Related]
54. Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors.
Ryan RM; Green J; Williams PJ; Tazzyman S; Hunt S; Harmey JH; Kehoe SC; Lewis CE
Gene Ther; 2009 Mar; 16(3):329-39. PubMed ID: 19177133
[TBL] [Abstract][Full Text] [Related]
55. Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models.
Lee CH; Wu CL; Shiau AL
J Gene Med; 2004 Dec; 6(12):1382-93. PubMed ID: 15468191
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
[TBL] [Abstract][Full Text] [Related]
57. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene.
Erbs P; Regulier E; Kintz J; Leroy P; Poitevin Y; Exinger F; Jund R; Mehtali M
Cancer Res; 2000 Jul; 60(14):3813-22. PubMed ID: 10919655
[TBL] [Abstract][Full Text] [Related]
58. Synergistic antitumor efficacy of suicide/ePNP gene and 6-methylpurine 2'-deoxyriboside via Salmonella against murine tumors.
Fu W; Lan H; Li S; Han X; Gao T; Ren D
Cancer Gene Ther; 2008 Jul; 15(7):474-84. PubMed ID: 18437183
[TBL] [Abstract][Full Text] [Related]
59. Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer.
Anderson LM; Swaminathan S; Zackon I; Tajuddin AK; Thimmapaya B; Weitzman SA
Gene Ther; 1999 May; 6(5):854-64. PubMed ID: 10505111
[TBL] [Abstract][Full Text] [Related]
60. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors.
Tai KF; Chen PJ; Chen DS; Hwang LH
J Gene Med; 2003 May; 5(5):386-98. PubMed ID: 12731087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]